title: Exposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preference.
abstract: Stress increases the risk of drug abuse, causes relapse to drug seeking, and potentiates the rewarding properties of both nicotine and cocaine. Understanding the mechanisms by which stress regulates the rewarding properties of drugs of abuse provides valuable insight into potential treatments for drug abuse. Prior reports have demonstrated that stress causes dynorphin release, activating kappa opioid receptors (KOR) in monoamine circuits resulting in both potentiation and reinstatement of cocaine and nicotine conditioned place preference. Here we report that kappa opioid-dependent reinstatement of cocaine and nicotine place preference is reduced when the mice are exposed to a randomized chronic mild stress (CMS) regime prior to training in a conditioned place preference-reinstatement paradigm. The CMS schedule involves seven different stressors (removal of nesting for 24 h, 5 min forced swim stress at 15°C, 8 h food and water deprivation, damp bedding overnight, white noise, cage tilt, and disrupted home cage lighting) rotated over a 3-week period. This response is KOR-selective, as CMS does not protect against cocaine or nicotine drug-primed reinstatement. This protection from reinstatement is also observed following sub-chronic social defeat stress, where each mouse is placed in an aggressor mouse home cage for a period of 20 min over 5 days. In contrast, a single acute stressor resulted in a potentiation of KOR-induced reinstatement, as previously reported. Prior studies have shown that stress alters sensitivity to opioids and prior stress can influence the pharmacodynamics of the opioid receptor system. Together, these findings suggest that exposure to different forms of stress may cause a dysregulation of kappa opioid circuitry and that changes resulting from mild stress can have protective and adaptive effects against drug relapse.
authors: Basic Research Division, Department of Anesthesiology, Washington University School of Medicine St. Louis, MO, USA ; Department of Anatomy and Neurobiology, Washington University School of Medicine St. Louis,MO, USA.
authors: Ream
authors: R
authors: Al-Hasani
authors: Jordan G
authors: JG
authors: McCall
authors: Michael R
authors: MR
authors: Bruchas
keywords: cocaine; conditioned place preference; kappa opioid receptor; nicotine; stress
references: J Neurosci. 2012 Sep 5;32(36):12325-36
references: 22956823
references: J Biol Chem. 2007 Oct 12;282(41):29803-11
references: 17702750
references: Pharmacol Biochem Behav. 2002 Oct;73(3):655-62
references: 12151041
references: J Pharmacol Exp Ther. 2006 Jan;316(1):440-7
references: 16223871
references: Psychopharmacology (Berl). 2001 Dec;158(4):388-98
references: 11797060
references: Neuron. 2011 Aug 11;71(3):498-511
references: 21835346
references: Neurosci Biobehav Rev. 2012 Oct;36(9):2085-117
references: 22776763
references: Psychopharmacology (Berl). 2008 Jul;199(1):1-14
references: 18470507
references: Neuropsychopharmacology. 2006 Apr;31(4):787-94
references: 16123754
references: Addict Biol. 2007 Sep;12(3-4):227-462
references: 17678505
references: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
references: 9636213
references: Annu Rev Med. 2011;62:431-45
references: 20707675
references: J Ethnopharmacol. 2008 May 8;117(2):257-62
references: 18339495
references: Psychopharmacology (Berl). 1999 May;144(2):183-8
references: 10395000
references: Am J Psychiatry. 2007 Aug;164(8):1149-59
references: 17671276
references: Brain Res Rev. 2009 Mar;59(2):253-77
references: 18762212
references: Brain Res. 2010 Feb 16;1314:44-55
references: 19716811
references: J Biol Chem. 2006 Jun 30;281(26):18081-9
references: 16648139
references: Psychopharmacology (Berl). 2013 Apr;226(4):763-8
references: 22526543
references: Biol Psychiatry. 2008 Jan 15;63(2):164-71
references: 17570348
references: J Biol Chem. 2004 Jan 16;279(3):1810-8
references: 14597630
references: Anesthesiology. 2011 Dec;115(6):1363-81
references: 22020140
references: Neuropsychopharmacology. 2013 Nov;38(12):2484-97
references: 23787819
references: J Lipid Res. 2008 Feb;49(2):340-8
references: 17991757
references: Pharmacol Rev. 2013 Jan 15;65(1):223-54
references: 23321159
references: Psychopharmacology (Berl). 2005 May;179(3):551-8
references: 15682306
references: Nat Rev Neurosci. 2004 Jun;5(6):483-94
references: 15152198
references: Nature. 2013 Jan 24;493(7433):537-541
references: 23235822
references: Psychopharmacology (Berl). 2005 Nov;183(1):118-26
references: 16184376
references: J Neurosci. 2012 Dec 5;32(49):17582-96
references: 23223282
references: Biol Psychiatry. 2011 Oct 15;70(8):744-753
references: 21757186
references: Psychopharmacology (Berl). 2008 Sep;200(1):59-70
references: 18575850
references: Neuron. 2008 Jul 10;59(1):11-34
references: 18614026
references: J Neurosci. 2008 Jan 9;28(2):407-14
references: 18184783
references: J Neuroinflammation. 2012 Jul 06;9:75
references: 22531370
references: Pharmacol Biochem Behav. 2012 May;101(3):434-42
references: 22330674
references: Nature. 1996 Feb 15;379(6566):606-12
references: 8628395
references: Eur J Pharmacol. 1986 Oct 14;130(1-2):65-72
references: 3780860
references: Brain Res. 2010 Feb 16;1314:162-74
references: 19765557
references: J Neurosci. 2007 Oct 24;27(43):11614-23
references: 17959804
references: Brain Res. 2008 Feb 27;1196:41-52
references: 18234161
references: Psychopharmacology (Berl). 2008 Apr;197(3):509-17
references: 18246329
references: J Pharmacol Exp Ther. 1994 Sep;270(3):1230-8
references: 7932176
references: Neuropharmacology. 2012 Jan;62(1):167-76
references: 21736885
references: Neuron. 2013 Mar 6;77(5):942-54
references: 23473323
references: Neuropsychopharmacology. 2008 Feb;33(3):643-52
references: 17473837
references: J Neurosci. 2012 Jan 25;32(4):1488-95
references: 22279233
references: Psychopharmacology (Berl). 2010 Jun;210(2):241-52
references: 20372879
references: Life Sci. 2007 Mar 20;80(15):1439-48
references: 17316701
references: Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19168-73
references: 19864633
references: J Pharmacol Exp Ther. 2003 Dec;307(3):1127-34
references: 14557376
references: J Neurosci. 2010 Feb 10;30(6):2300-10
references: 20147556
references: Addict Biol. 2011 Jan;16(1):116-9
references: 20579007
references: Nature. 2012 Oct 18;490(7420):402-6
references: 22992525
references: Neurosci Biobehav Rev. 2012 May;36(5):1418-41
references: 22405889
references: Psychopharmacology (Berl). 2010 Jun;210(2):121-35
references: 20352414
references: Neuropharmacology. 2011 Feb-Mar;60(2-3):303-11
references: 20854830
references: J Neurosci. 2003 Jul 2;23(13):5674-83
references: 12843270
references: Neuroscience. 1997 Sep;80(1):17-20
references: 9252217